menu search

Clearside Biomedical Opens Enrollment in ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD

Clearside Biomedical Opens Enrollment in ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD
– U.S. Clinical Sites Screening Treatment-Experienced Participants with Wet AMD – – ODYSSEY Topline Results Expected in Q3 2024 – ALPHARETTA, Ga., June 01, 2023 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that enrollment […] The post Clearside Biomedical Opens Enrollment in ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injec... Read More
Posted: Jun 1 2023, 11:05
Author Name: forextv
Views: 081332

Search within

Pages Search Results: